ENTA Stock Analysis: Buy, Sell, or Hold?
ENTA - Enanta Pharmaceuticals, Inc
$13.47
0.34 (2.59%)
â˛
5d:
+2.36%
30d:
+4.02%
90d:
-2.6%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When ENTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ENTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ENTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ENTA is currently trading at $13.47, which is considered slightly high relative to its 30-day fair value range of $12.82 to $13.54.
Technical Outlook: Technically, ENTA is showing sideways momentum. Immediate support is located at $12.59, while resistance sits at $13.98.
Market Sentiment: ENTA scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (80th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $21.17 (+57.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENTA is showing sideways momentum. Immediate support is located at $12.59, while resistance sits at $13.98.
Market Sentiment: ENTA scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (80th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $21.17 (+57.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$12.82 -
$13.54
Company Quality Score
51/100
(HOLD)
Options IV Signal
80th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
33.3%
Protect Your Profits
Holding ENTA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Options expensive (IV 80th percentile)
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 57.1% below Wall St target ($21.17)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$12.82 -
$13.54
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$2.17
(16.1%)
Support & Resistance Levels
Support Level
$12.59
Resistance Level
$13.99
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.79
Wall Street Target
$21.17
(+57.1%)
Revenue Growth (YoY)
-21.6%
Earnings Growth (YoY)
-66.2%
Profit Margin
-96.9%
Share & Embed Analysis
Last updated: August 24, 2026 7:10 AM ET
Data refreshes hourly during market hours. Next update: 8:10 AM
Data refreshes hourly during market hours. Next update: 8:10 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$560 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
Advanced ENTA Option Strategies
Professional options setups generated by AI based on today's ENTA price and gamma walls.
